Somewhat Positive Press Coverage Somewhat Unlikely to Affect OncoSec Medical (ONCS) Share Price
News stories about OncoSec Medical (NASDAQ:ONCS) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoSec Medical earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5152337604288 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- OncoSec Medical (ONCS) Scheduled to Post Quarterly Earnings on Wednesday (americanbankingnews.com)
- OncoSec Medical : Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform (4-traders.com)
- OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform (finance.yahoo.com)
- OncoSec Medical Incorporated, (NASDAQ: ONCS), Babcock … – Stocks In The News (press release) (tradingnewsnow.com)
- OncoSec Medical Incorporated (ONCS) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
ONCS has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of OncoSec Medical in a research report on Thursday, November 9th. Maxim Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Tuesday, October 10th. Finally, ValuEngine raised shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. OncoSec Medical currently has an average rating of “Buy” and a consensus price target of $5.33.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). sell-side analysts forecast that OncoSec Medical will post -0.86 EPS for the current year.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.